Last reviewed · How we verify
Acute promyelocytic leukemia, FAB M3
Approved treatments
- Daunorubicin Hydrochloride · Meiji Seika Pharma Co., Ltd
- Trisenox · Cephalon
- Idamycin Pfs · Pfizer Inc.
Idarubicin forms DNA complexes, inhibits nucleic acid synthesis and topoisomerase II, produces DNA-damaging free radicals. - Daunorubicine · Gruppo Italiano Malattie EMatologiche dell'Adulto
- Cytarabine · Nippon Shinyaku Co., Ltd.
Cytarabine inhibits DNA polymerase and incorporates into DNA/RNA, killing cells in S-phase. - 6-Mercaptopurine · Pfizer Inc.
- Retin-A · Bausch Health
Tretinoin works by binding to and activating nuclear receptors, which helps to regulate cell growth and differentiation. - Trisenox · German AML Cooperative Group
- Purixan · Stason Pharms
Purixan works by inhibiting the enzyme responsible for producing prostaglandins, which are involved in inflammation and immune response. - Idamycin Pfs
Idarubicin hydrochloride exerts its effects by forming DNA complexes, inhibiting nucleic acid synthesis, blocking topoisomerase II, and generating DNA-damaging free radicals. - Idamycin Pfs
Idarubicin works by binding to DNA topoisomerase 2-alpha, preventing the enzyme from unwinding DNA and leading to cell death. - Xaluprine · Kjeld Schmiegelow
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Acute promyelocytic leukemia, FAB M3 patent landscape — cliff calendar, originator estates, attackable patents
- Acute promyelocytic leukemia, FAB M3 treatment landscape brief
- Acute promyelocytic leukemia, FAB M3 treatment updates RSS
Frequently asked questions about Acute promyelocytic leukemia, FAB M3
What drugs treat Acute promyelocytic leukemia, FAB M3?
Tracked treatments include Daunorubicin Hydrochloride, Trisenox, Idamycin Pfs, Daunorubicine, Cytarabine, 6-Mercaptopurine, Retin-A, Purixan.
What is the treatment for Acute promyelocytic leukemia, FAB M3?
Standard treatment for Acute promyelocytic leukemia, FAB M3 includes Daunorubicin Hydrochloride, Trisenox, Idamycin Pfs, Daunorubicine, Cytarabine. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Acute promyelocytic leukemia, FAB M3 patent cliff · Acute promyelocytic leukemia, FAB M3 CI report
- Treatment: Daunorubicin Hydrochloride · Meiji Seika Pharma Co., Ltd
- Treatment: Trisenox · Cephalon
- Treatment: Idamycin Pfs · Pfizer Inc.
- Treatment: Daunorubicine · Gruppo Italiano Malattie EMatologiche dell'Adulto
- Treatment: Cytarabine · Nippon Shinyaku Co., Ltd.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing